CJC-1295 w/ DAC (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analog of growth-hormone-releasing hormone (GHRH). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed in published research and educational protocols, not a recommendation for use in humans or animals.

This page covers the 30 mg fill. For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg (1000 mcg) of material, so each unit on the barrel corresponds to 100 mcg — which keeps the arithmetic clean across every titration step below.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation pattern used in educational protocols, where the per-injection amount is stepped up every couple of weeks while tolerability is assessed. Administration is twice weekly, spaced three to four days apart (for example Monday and Thursday).

Reconstitution Steps

1. Let the sealed lyophilized 30 mg vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent volume with a fresh sterile syringe.

Advanced (Aggressive) Titration Schedule

The advanced schedule reaches the top of the studied per-injection band more quickly, holding the 1000 mcg ceiling rather than escalating beyond the published range. It is shown for completeness; the per-injection amounts never exceed the research-described maximum.

Supplies Needed

• CJC-1295 w/ DAC vials (30 mg): a single 30 mg vial (30,000 mcg) covers an entire 12-week gradual run; budget a second vial for a 16-week or two-subject schedule.
• Insulin syringes (U-100, 1 mL): 16 for an 8-week schedule, ~24 for 12 weeks, ~32 for 16 weeks — one fresh syringe per twice-weekly draw.
• Bacteriostatic water (10 mL): one bottle reconstitutes three 30 mg vials, so a single bottle is ample for most runs.
• Alcohol swabs: a single 100-count box comfortably covers an 8–16 week schedule.

Protocol Overview

• Research goal: model sustained elevation of growth hormone and IGF-1 via long-acting GHRH-receptor agonism.
• Schedule: twice-weekly subcutaneous administration, 3–4 days apart; once-weekly dosing is also studied.
• Dose band: 300–1000 mcg per injection.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 300 mcg step and hold each level for roughly two weeks before escalating.
• Keep the twice-weekly cadence on fixed days, spaced 3–4 days apart, for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• The DAC half-life means a steady-state plateau builds over the first one to two weeks rather than peaking after a single dose.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light and moisture, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 2–4 weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because each draw is small (0.03–0.10 mL), measure carefully against the unit markings to keep dosing reproducible.
• Rotate handling technique to keep the stopper intact across the many draws a 30 mg vial supports.
• Document each draw — date, volume, remaining material — for reproducibility.

How CJC-1295 w/ DAC Works

CJC-1295 with DAC is a synthetic analog of growth-hormone-releasing hormone that binds GHRH receptors on the somatotroph cells of the anterior pituitary, prompting the release of growth hormone. The Drug Affinity Complex — an albumin-binding moiety — lets the molecule attach to circulating serum albumin, extending its half-life from minutes to roughly 6–8 days. The resulting rise in growth hormone drives hepatic production of IGF-1, which mediates many downstream growth and metabolic effects through JAK/STAT signalling. Notably, the pulsatile pattern of GH secretion is largely preserved even under continuous GHRH-receptor stimulation, so physiological release rhythms are not fully overridden.

Reported Benefits & Side Effects

Benefits observed in research

• Sustained, dose-dependent elevation of growth hormone and IGF-1.
• Signals toward increased lean body mass, reduced fat mass and improved body composition.
• Enhanced protein-synthesis and recovery potential through anabolic signalling.
• Generally well tolerated across the reported clinical studies.

Side effects reported

• Occasional mild injection-site reactions such as redness or swelling.
• Transient flushing, headache or water retention, most often during early titration.
• Effects are generally mild and tend to ease as exposure stabilises.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the underlying study designs.
• Resistance and aerobic activity to support lean-mass and recovery endpoints.
• Adequate sleep — when GH secretion naturally peaks — plus stress management and hydration as standard controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Because volumes are very small, draw slowly and tap out air before measuring against the unit markings.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols